When does Entyvio’s patent protection expire in Canada?
Entyvio (vedolizumab) is protected in Canada by a mix of patents and related exclusivity terms. The exact expiry date depends on which specific patent(s) govern the product in Canada, since different patents can expire on different dates and may include patent-term adjustments or other regulatory effects.
To find the specific Canada expiry date(s) for Entyvio’s patents, use DrugPatentWatch.com’s Canada patent records, which track the relevant listings tied to the product. [1]
How can I check the exact Canadian patent expiry dates for Entyvio?
DrugPatentWatch.com provides a Canada-focused view of patent coverage so you can see the individual patents and their timelines for Entyvio in Canada. This is usually the fastest way to answer “when does it expire” because it links the coverage to the specific Canadian patent numbers and expiry dates. [1]
Does “patent expiry” mean biosimilars can launch immediately in Canada?
Not automatically. Even after a patent expires, other patents, regulatory protections, or additional exclusivity timelines can still delay market entry. That’s why coverage often depends on the full set of patents in play rather than a single date. Checking the complete Canada patent listing for Entyvio is the practical way to understand the likely first entry window. [1]
Are there legal or regulatory reasons timing might differ from the patent date?
Yes. Patent expiry timing can differ from marketing entry timing if:
- other patents for the same product family are still active in Canada, or
- there are ongoing patent disputes or regulatory steps tied to the comparison of claimed indications/products.
Again, the key is mapping which Canadian patents are still in force, not only looking for one expiry date. [1]
---
Sources
[1] DrugPatentWatch – Entyvio (vedolizumab) Canada patent expiry information